2.64

1.15% 0.03

Pre-market: 2.65 0.010 +0.38%

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $2.64, with a volume of 3.50M. It is up +1.15% in the last 24 hours and down -7.37% over the past month. Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Previous Close:

$2.61

Open:

$2.62

24h Volume:

3.50M

Relative Volume:

0.94

Market Cap:

$513.41M

Revenue:

$36,000

Net Income/Loss:

$-91.08M

P/E Ratio:

-2.8157

EPS:

-0.9376

Net Cash Flow:

$-71.67M

1W Performance:

-3.30%

1M Performance:

-7.37%

6M Performance:

-50.00%

1Y Performance:

-61.85%

1-Day Range:

$2.58

$2.676

1-Week Range:

$2.5702

$2.80

52-Week Range:

$2.56

$7.73

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	2.64	513.41M	36,000	-91.08M	-71.67M	-0.9376
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Upgrade	Goldman	Sell → Neutral
Mar-18-26	Initiated	Truist	Buy
Jan-28-26	Initiated	Barclays	Overweight
Jul-10-25	Resumed	Goldman	Sell
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

Jun 15, 2026

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits

Jun 15, 2026

Jun 14, 2026

Altimmune sets pemvidutide's phase 3 MASH playbook as AUD data near - MSN

Jun 14, 2026

ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN

Jun 14, 2026

LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits

Jun 14, 2026

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Yahoo Finance

Jun 10, 2026

Jun 08, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.

Jun 08, 2026

Altimmune Shares Drop After $225 Million Offering Prices - Moomoo

Jun 08, 2026

ALT and the Rise of Dual Agonists Targeting Liver Disease - Yahoo Finance

Jun 08, 2026

ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup - Yahoo Finance

Jun 08, 2026

Is Altimmune Worth Buying Ahead of 2026 Catalysts? - Yahoo Finance

Jun 08, 2026

Altimmune (ALT) Gains Ground Amid Positive Momentum, Testing Key Resistance LevelsHedge Fund Exposure - newsline.com

Jun 08, 2026

Jun 07, 2026

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits

Jun 07, 2026

Jun 04, 2026

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial - Barchart.com

Jun 04, 2026

Altimmune director Gill buys $31k in company stock - Investing.com

Jun 04, 2026

ALT: Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment - TradingView

Jun 04, 2026

Jun 02, 2026

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - TMX Newsfile

Jun 02, 2026

Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com

Jun 02, 2026

Citizens reiterates Altimmune stock rating on fibrosis trial data By Investing.com - Investing.com Canada

Jun 02, 2026

Jun 01, 2026

ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

Jun 01, 2026

May 31, 2026

Altimmune (MEX:ALT1) Other Liabilities for Banks - GuruFocus

May 31, 2026

May 29, 2026